Immix Biopharma (IMMX) Debt to Equity (2020)

Immix Biopharma's (IMMX) quarterly Debt to Equity came in at -$0.12 in Q4 2020.

Immix Biopharma (IMMX) Debt to Equity (2020) Analysis & Trends

Immix Biopharma has disclosed Debt to Equity across 1 years of filings, most recently posting -$0.12 for Q4 2020.

Debt to Equity for Q4 2020 came in at -$0.12, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was -$0.12 (changed N/A YoY), and the FY2020 annual result was -$0.12, changed N/A from the prior year.
Debt to Equity came in at -$0.12 for Q4 2020 at Immix Biopharma.
In the past five years, Debt to Equity ranged from a high of -$0.12 in Q4 2020 to a low of -$0.12 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.32
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Immix Biopharma	467.59 Mn	467.59 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	-0.12